Aflibercept: all 271 studies that test it
Page 3 of 3. Open to participants first (12), then studies with results posted, then the rest; newest registration first within each.
- Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)CompletedNCT02537054Phase 2
- Randomized, Double-masked, Sham-controlled Phase 4 Study, Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Monotherapy Compared to Aflibercept With Adjunctive Photodynamic Therapy in Patients With Polypoidal Choroidal VasculopathyCompletedNCT02495181Phase 4
- Ziv-aflibercept in Ocular Disease Requiring Anti-VEGF InjectionStatus unknownNCT02486484Phase 2
- Predictors of Treatment Response to Aflibercept and Aqueous Cytokine Levels in Diabetic Macular EdemaCompletedNCT02441907Phase 4
- VITAL - Individualising Therapy for Neovascular AMD With AfliberceptCompletedNCT02441816Phase 4
- Intravitreal Aflibercept Injection for Symptomatic Macular Edema From Retinal Artery MacroaneurysmsStatus unknownNCT02403128Phase 1
- A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular DegenerationCompletedNCT02401945Phase 2
- Variable Interval Versus Set Interval Aflibercept for DMECompletedNCT02392364Phase 4
- Assessment of Visual Acuity in Patients With Polypoidal Choroidal Vasculopathy and Aflibercept TreatmentCompletedNCT02381730Not applicable
- PERMAD: Personalized Marker-driven Early Switch to Aflibercept in Patients With Metastatic Colorectal CancerStatus unknownNCT02331927Phase 2
- Cohort Study of the Clinical Course of Macular Diseases in KagawaStatus unknownNCT02321267Phase 4
- Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)CompletedNCT02320474Phase 4
- Intravitreal Aflibercept in Neovascular AMD With Limited Response to RanibizumabCompletedNCT02309281Phase 4
- Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced CancerActive, not recruitingNCT02298959Phase 1
- The Endurance 1 TrialCompletedNCT02297204Phase 4
- Comparison of Pharmacokinetics of and Effect on Systemic VEGF Levels in Age Related Macular Degeneration PatientsStatus unknownNCT02296567Phase 2/3
- Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend RegimenCompletedNCT02274259Phase 4
- Systemic VEGF Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Visual Impairment Due to Diabetic Macular EdemaWithdrawnNCT02258009Phase 4
- Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young PatientsCompletedNCT02257502Phase 2
- Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal CancerWithdrawnNCT02235324Phase 2
- Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular DegenerationCompletedNCT02204683Phase 1
- A Pharmacokinetic Study: Ranibizumab, Aflibercept and the Effect of Vitrectomy.CompletedNCT02174211Not applicable
- Ziv-aflibercept in Eyes With Retinal Diseases and Poor Vision-phase IStatus unknownNCT02173873Phase 1
- Eylea to Treat Retinal Pigment Epithelial Detachment (RPED) Secondary to Wet Age-Related Macular Degeneration (wAMD)CompletedNCT02142296Phase 4
- Clinical Trial of Combination Chemotherapy With Aflibercept in Patients With Advanced Colorectal CancerCompletedNCT02129257Phase 2
- Efficacy and Safety of Intravitreal Vascular Endothelial Growth Factor Trap-eye in Patients With Polyploidal Choroidal VasculopathyCompletedNCT02072408Phase 4
- Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal CancerTerminatedNCT02045030Phase 2
- Aflibercept Intravitreal Injection for Myopic Choroidal NeovascularizationStatus unknownNCT02033018Phase 4
- Intravitreal Aflibercept in Wet Age Related Macular Degeneration Patients With an Incomplete Response to Routine Ranibizumab InjectionsTerminatedNCT02002377Phase 4
- Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous ChorioretinopathyCompletedNCT01971190Phase 2
- Intravitreal Aflibercept Injections In The Treatment Of Pattern DystrophyWithdrawnNCT01965041Not applicable
- Treat and Extend Therapy Study Using Intravitreal Aflibercept for Patients Exited From Protocol VGFT-OD 0910Status unknownNCT01961414Phase 4
- Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination ChemotherapyWithdrawnNCT01941173Not applicable
- Aflibercept (EYLEA)as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration.Status unknownNCT01918878Phase 4
- Study to Evaluate Efficacy of Aflibercept in Neovascular Age-related Macular Degeneration Patients Non Responders to Anti-Vascular Endothelial Growth FactorCompletedNCT01896284Phase 4
- Safety and Effectiveness Study of Chemotherapy and Ziv-aflibercept to Treat Metastatic Colorectal CancerWithdrawnNCT01889680Phase 2
- Intravitreal Aflibercept Injection for Polypoidal Choroidal Vasculopathy With Hemorrhage or ExudationCompletedNCT01871376Phase 4
- NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein OcclusionsCompletedNCT01870427Phase 4
- Using Aflibercept Injection to Treat Blood Vessel Growth Over the CorneaTerminatedNCT01868360Phase 1
- Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF TherapyStatus unknownNCT01857544Phase 4
- Study of PRN and Every 2months Intravitreal Aflibercept for Age Related Macular DegenerationCompletedNCT01824225Phase 4
- Treatment With Intravitreal Aflibercept Injection For Proliferative Diabetic Retinopathy, The A.C.T StudyCompletedNCT01813773Phase 2/3
- OPTIMOX-aflibercept as First-line Therapy in Patients With Unresectable Metastatic Colorectal CancerCompletedNCT01802684Phase 2
- Treatment for Presumed Ocular HistoplasmosisStatus unknownNCT01790893Phase 1/2
- A Study Testing if Medicine Can Make Pigment Epithelium Detachments Regress and Stabilize the Vision in EyesTerminatedNCT01746875Not applicable
- Impact of Intravitreal Aflibercept Injections on Capillary Non-PerfusionCompletedNCT01724554Phase 1/2
- Intravitreal Aflibercept Injection for the Treatment of Submacular Vascularized Pigment Epithelial DetachmentCompletedNCT01722656Phase 4
- Nesvacumab (REGN910/ SAR307746) and Aflibercept ("Ziv-aflibercept" in the U.S.) in Patients With Advanced Solid MalignanciesCompletedNCT01688960Phase 1
- On-label tReatment With Intravitreal Aflibercept injectiOn for Patients With Persistent Pigment epitheliaL Detachments in Neovascular Age Related Macular Degeneration (AMD)Status unknownNCT01670162Phase 4
- Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term ResultsStatus unknownNCT01657669Phase 4
- Efficacy of FOLFOX Versus FOLFOX Plus Aflibercept in K-ras Mutant Patients With Resectable Liver MetastasesWithdrawnNCT01646554Phase 2/3
- Intravitreal Aflibercept Injection for Radiation RetinopathyCompletedNCT01579760Phase 1
- Intravitreal Aflibercept Injection (IAI) for Presumed Ocular Histoplasmosis SyndromeCompletedNCT01578720Phase 1
- Japanese Safety Study of VEGF Trap-Eye in DME (Diabetic Macular Edema)CompletedNCT01512966Phase 3
- Open Label to Study to Evaluate Effect of Alfilbercept on Patients With (FVPED) Fibrovascular Pigment Epithelial DetachmentWithdrawnNCT01495208Phase 4
- A Study of Intravenous Aflibercept With Docetaxel in Chinese Patients With Solid TumorsCompletedNCT01148615Phase 1
- Study of Intravenous Aflibercept in Combination With FOLFIRI in Japanese Patients With Metastatic Colorectal CancerCompletedNCT00921661Phase 1
- A Study to Evaluate the Effects of Aflibercept on QTc Interval in Cancer PatientsCompletedNCT00876044Phase 1
- Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant GliomaCompletedNCT00650923Phase 1
- Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell LymphomaCompletedNCT00644124Phase 1
- Aflibercept in Treating Young Patients With Relapsed or Refractory Solid TumorsCompletedNCT00622414Phase 1
- A Multi-Center Phase 2 Study of VEGF Trap as a Single Agent in Acute Myeloid LeukemiaWithdrawnNCT00601991Phase 2
- A Phase I Study of Intravenous Aflibercept in Combination With Docetaxel in Japanese Cancer PatientsCompletedNCT00545246Phase 1
- A Phase I Study of Intravenous Aflibercept in Combination With S-1 in Japanese Cancer PatientsCompletedNCT00479076Phase 1
- Safety and Tolerability of Intravitreal VEGF Trap Formulations in Subjects With Neovacular AMDCompletedNCT00383370Phase 1
- Phase 1 Study of VEGF Trap in Patients With Diabetic Macular EdemaCompletedNCT00320814Phase 1
- Safety and Tolerability Study of Intravitreal VEGF-Trap Administration in Patients With Neovascular AMDCompletedNCT00320775Phase 1
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00083213Phase 1
- Intravenous VEGF Trap in Treating Patients With Relapsed or Refractory Advanced Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00082823Phase 1
- VEGF Trap in Treating Patients With Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00045266Phase 1
- VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's LymphomaCompletedNCT00036946Phase 1